These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 17175328

  • 21. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
    Hayakawa Y, Tamaki N, Nakanishi H, Kurosaki M, Tanaka Y, Inada K, Ishido S, Kirino S, Yamashita K, Nobusawa T, Matsumoto H, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Okamoto R, Izumi N.
    Intern Med; 2023 Apr 01; 62(7):973-978. PubMed ID: 36070941
    [Abstract] [Full Text] [Related]

  • 22. Factors affecting compliance and persistence with treatment for hepatic encephalopathy.
    Neff G.
    Pharmacotherapy; 2010 May 01; 30(5 Pt 2):22S-7S. PubMed ID: 20412037
    [Abstract] [Full Text] [Related]

  • 23. The Health Care Burden of Hepatic Encephalopathy.
    Elsaid MI, John T, Li Y, Pentakota SR, Rustgi VK.
    Clin Liver Dis; 2020 May 01; 24(2):263-275. PubMed ID: 32245532
    [Abstract] [Full Text] [Related]

  • 24. Treatment of Acute Hepatic Encephalopathy: Comparing the Effects of Adding Rifaximin to Lactulose on Patient Outcomes.
    Courson A, Jones GM, Twilla JD.
    J Pharm Pract; 2016 Jun 01; 29(3):212-7. PubMed ID: 25586470
    [Abstract] [Full Text] [Related]

  • 25. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO, Eaton-Maxwell A.
    Ann Pharmacother; 2009 Jan 01; 43(1):77-84. PubMed ID: 19092143
    [Abstract] [Full Text] [Related]

  • 26. Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.
    Jesudian AB, Ahmad M, Bozkaya D, Migliaccio-Walle K.
    J Manag Care Spec Pharm; 2020 Jun 01; 26(6):750-757. PubMed ID: 32463782
    [Abstract] [Full Text] [Related]

  • 27. Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment.
    Fritz MK, Mangino AA, Hunt TV, Pitcock CT, Dugan AJ, Karri K, Yarra P.
    Ann Pharmacother; 2023 Aug 01; 57(8):899-906. PubMed ID: 36367093
    [Abstract] [Full Text] [Related]

  • 28. Lack of Access to Rifaximin Upon Hospital Discharge Is Frequent and Results in Increased Hospitalizations for Hepatic Encephalopathy.
    Stoll AM, Guido M, Pence A, Gentene AJ.
    Ann Pharmacother; 2023 Feb 01; 57(2):133-140. PubMed ID: 35658580
    [Abstract] [Full Text] [Related]

  • 29. Review article: the modern management of hepatic encephalopathy.
    Bajaj JS.
    Aliment Pharmacol Ther; 2010 Mar 01; 31(5):537-47. PubMed ID: 20002027
    [Abstract] [Full Text] [Related]

  • 30. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
    Hasan S, Datta S, Bhattacherjee S, Banik S, Saha S, Bandyopadhyay D.
    J Assoc Physicians India; 2018 Jan 01; 66(1):32-6. PubMed ID: 30341842
    [Abstract] [Full Text] [Related]

  • 31. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
    Bajaj JS, O'Leary JG, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Lai J, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR.
    Aliment Pharmacol Ther; 2019 Jun 01; 49(12):1518-1527. PubMed ID: 31032966
    [Abstract] [Full Text] [Related]

  • 32. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
    Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, Chon CY, Lee SI, Moon YM.
    Yonsei Med J; 2005 Jun 30; 46(3):399-407. PubMed ID: 15988813
    [Abstract] [Full Text] [Related]

  • 33. Combination therapy for the treatment and prevention of hepatic encephalopathy.
    Mohammad RA, Regal RE, Alaniz C.
    Ann Pharmacother; 2012 Nov 30; 46(11):1559-63. PubMed ID: 23092866
    [Abstract] [Full Text] [Related]

  • 34. Optimal treatment of hepatic encephalopathy.
    Waghray A, Waghray N, Kanna S, Mullen K.
    Minerva Gastroenterol Dietol; 2014 Mar 30; 60(1):55-70. PubMed ID: 24632768
    [Abstract] [Full Text] [Related]

  • 35. ACP Journal Club. Adding rifaximin to lactulose increased reversal and decreased mortality in hepatic encephalopathy.
    Kowdley KV, Burman BE.
    Ann Intern Med; 2013 Oct 15; 159(8):JC8. PubMed ID: 24126669
    [No Abstract] [Full Text] [Related]

  • 36. Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs.
    Jesudian AB, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Chen J, Guérin A, Bumpass B, Borroto D, Joseph G, Dashputre AA.
    J Med Econ; 2023 Oct 15; 26(1):1169-1177. PubMed ID: 37664993
    [Abstract] [Full Text] [Related]

  • 37. Impact of rifaximin use for hepatic encephalopathy on the risk of early post-transplant infections in liver transplant recipients.
    Sun HY, Wagener M, Cacciarelli TV, Singh N.
    Clin Transplant; 2012 Oct 15; 26(6):849-52. PubMed ID: 22432742
    [Abstract] [Full Text] [Related]

  • 38. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients.
    Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM.
    Aliment Pharmacol Ther; 2010 May 15; 31(9):1012-7. PubMed ID: 20136802
    [Abstract] [Full Text] [Related]

  • 39. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
    Sidhu SS, Goyal O, Parker RA, Kishore H, Sood A.
    Liver Int; 2016 Mar 15; 36(3):378-85. PubMed ID: 26201713
    [Abstract] [Full Text] [Related]

  • 40. Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands.
    de Jong LA, van Schoonhoven AV, Hofstra HS, Postma MJ, van Hoek B.
    J Med Econ; 2021 Mar 15; 24(1):1149-1163. PubMed ID: 34629016
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.